Dr Senthil Sockalingam,
Head of IQVIA Biotech (Asia Pacific), Singapore
In JAPAC alone, just under 7000 studies were launched by mid- and small-size EBPs between 2016 and 2020. Indeed, the expansion is complemented with IQVIA Biotech’s advanced analytics and technology solutions for clinical research programmes which assist in clinical progress of biologics, drugs, and vaccines. Speaking with BioSpectrum Asia, Dr Senthil Sockalingam, Head of IQVIA Biotech (Asia Pacific), Singapore shares the aspirations and goals of new JAPAC expansion dedicated to biotech and emerging biopharma industries. Edited excerpts;
How significant is the recent expansion to JAPAC and what are the key performance goals?
JAPAC (Asia Pacific and Japan) is an increasingly important location for clinical trials. The region accounts for close to 60 per cent of the world’s population and presents high disease burdens, fast-improving infrastructure, clinical trial recruitment and regulatory efficiencies, globally leading data management innovation, and, increasingly, greater government support of clinical research.
Clinical trial sites set up by biotech and biopharma companies in JAPAC have increased by over 40 per cent each year on average, compared to just 11 per cent across the rest of the world. There are a lot of biotech companies coming to JAPAC to run their clinical programmes and wanting to launch their drugs in the region given the attractive market dynamics. Given the rise of the region and the globalisation of drug development, especially around emerging biopharma (EBPs), it was a good time to launch IQVIA Biotech in JAPAC.
This story is from the BioSpectrum Asia August 2021 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia August 2021 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.